Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by Farmer9on Sep 02, 2013 7:43pm
207 Views
Post# 21713675

RE:What was the point for Dart's private placement

RE:What was the point for Dart's private placementWhy did the company need $1.6 million?  Probably to keep the doors open.  They actually need a lot more cash.  They have $50 million in liabilities and $17 million in cash. 

From the annual finacial statements releases July 26, 2013:
"Resverlogix Corp. has insufficient cash to fund contractual
commitments due in the next 12 months. This condition, along with the working capital deficiency of $4.2 million as at April 30, 2013, and other matters as set forth in Note 2 in the consolidated financial statements, indicates the existence of a material uncertainty that may cast significant doubt about Resverlogix Corp.’s ability to continue as a going concern.

Where is the silver lining in these FACTS?????


Bullboard Posts